P/E Ratio (TTM)
-19.69
NewAmsterdam Pharma Company N.V. currently has a P/E ratio of -19.69. The P/E ratio is a primary valuation multiple used to determine if a stock is overvalued or undervalued relative to its earnings.
Quarterly P/E
| Quarter | P/E Ratio |
|---|---|
| 2020-03-31 | -158.98 |
| 2020-06-30 | -158.98 |
| 2020-09-30 | -158.98 |
| 2020-12-31 | 1136.07 |
| 2021-03-31 | -7.95 |
| 2021-06-30 | -7.70 |
| 2021-09-30 | -3.94 |
| 2021-12-31 | -2.15 |
| 2022-03-31 | 1.45 |
| 2022-06-30 | 1.53 |
| 2022-09-30 | -1.16 |
| 2022-12-31 | -1.31 |
| 2023-03-31 | -6.44 |
| 2023-06-30 | -6.35 |
| 2023-09-30 | -4.05 |
| 2023-12-31 | -4.65 |
| 2024-03-31 | -4.68 |
| 2024-06-30 | -12.49 |
| 2024-09-30 | -23.62 |
| 2024-12-31 | -6.76 |
| 2025-03-31 | -15.03 |
| 2025-06-30 | -29.34 |
| 2025-09-30 | -11.75 |
| 2025-12-31 | -13.39 |
Annual P/E
| Year | P/E Ratio |
|---|
* P/E ratios are calculated using trailing twelve-month (TTM) earnings. Extreme values may indicate earnings anomalies or cyclical volatility.